clinical trial · NCT06680128
A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults
SK Bioscience Co., Ltd.·phase2·recruiting·n = 402
Japanese Encephalitis Virus DiseaseGBP560-AGBP560-BIXIAROIMOJEVNormal Saline (Placebo)
brief summary
This is a 2-Stage, Phase I/II Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis mRNA Vaccines (GBP560) in Healthy Adults (Aged 18 Years and Older)
started
Feb 24, 2025
primary completion
Jun 26, 2026
completion
Mar 19, 2028
last updated
Dec 23, 2025
detailed description
The purpose of this study is to assess the safety, reactogenicity and immunogenicity of SK Japanese Encephalitis mRNA vaccines (GBP560) in healthy adults.
official title
A 2-Stage, Phase I/II, Active-controlled, Randomized, Observer-blinded, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis mRNA Vaccines (GBP560) in Healthy Adults (Aged 18 Years and Older)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol